Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Erba on Second-Generation TKIs for Chronic Phase CML

March 18th 2013

Harry Erba, MD, PhD, from the University of Alabama at Birmingham, discusses the use of second-generation tyrosine kinase inhibitors for the treatment of chronic phase chronic myeloid leukemia.

Dr. Berenson on Carfilzomib in Refractory Multiple Myeloma

March 15th 2013

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, discusses the a study of carfilzomib as a replacement for bortezomib for multiple myeloma patients refractory to a bortezomib-containing combination regimen.

Dr. Pinter-Brown on CTCL Combination Therapies

March 13th 2013

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses combination therapies in cutaneous T-cell lymphoma.

Study Supports Chemotherapy-Free Strategy in Acute Promyelocytic Leukemia

March 13th 2013

A treatment regimen rooted in traditional Chinese philosophy has emerged as a targeted approach for patients with newly diagnosed, lower-risk acute promyelocytic leukemia.

Dr. Advani Discusses Outcomes in ALCL

March 11th 2013

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses outcomes for patients with anaplastic large-cell lymphoma.

Making Time for Innovation: Myeloma Expert Sets Brisk Pace of Discovery

March 11th 2013

Working in the laboratory and the clinic, Shaji K. Kumar, MD, has made a discovery: that there aren't enough hours in a day.

ASH Sunday

March 8th 2013

On Sunday, December 9, 2012, the Plenary Session at the 54th American Society of Hematology Annual Meeting featured several noteworthy abstracts.

Dr. Zelenetz on Treating Hematologic Malignancies

March 6th 2013

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, describes challenges and emerging treatment approaches for patients with hematologic malignancies.

Study Confirms Treatment Target in Patients With Polycythemia Vera

March 6th 2013

Patients with the rare form of blood cancer polycythemia vera whose hematocrit levels hover between 45% and 50% have a four-fold higher incidence of thrombotic complications.

Dr. Ari Melnick on MALT1 as a Potential Target in DLBCL

March 5th 2013

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses MALT1 as a potential target for patients with activated B cell-like diffuse large B-cell lymphoma.

Dr. Richard T. Silver Discusses the Use of Interferons in MPNs

March 1st 2013

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use of interferons in myeloproliferative neoplasms.

Dr. Mesa on the Role of JAK2 Inhibitors in Myelofibrosis

February 28th 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the use of JAK2 inhibitors in patients with myelofibrosis.

Dr. Landgren on Maintenance Therapy in Myeloma

February 25th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the pros and cons of maintenance therapy for patients with myeloma.

Novel TKI Quizartinib Sparks Remission in Some Patients With Resistant AML

February 22nd 2013

Quizartinib, an investigational tyrosine kinase inhibitor, demonstrated a clinical benefit in patients with a particularly deadly form of acute myeloid leukemia.

Dr. Jennifer Brown on Gauging Response in CLL

February 20th 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses gauging response in chronic lymphocytic leukemia.

Ibrutinib Receives Breakthrough Designations for Mantle Cell Lymphoma and WaldenstrÃ¶m's Macroglobulinemia

February 13th 2013

The investigational agent ibrutinib was granted "Breakthrough Therapy Designations" by the FDA as a singular therapy for a pair of B-cell malignancies: relapsed or refractory mantle cell lymphoma and WaldenstrÃ¶m's macroglobulinemia.

Dr. Francesco Lo-Coco on Arsenic Trioxide in APL

February 13th 2013

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide (ATO), in acute promyelocytic leukemia (APL).

Biotech Focus: Tracking the Oncology Pipeline

February 13th 2013

Several updates highlighted at the 2012 American Society of Hematology Annual Meeting as well as other developments.

Dr. Fanale on the Potential of Antibody-Drug Conjugates

February 12th 2013

Michelle A. Fanale, MD, from the MD Anderson Cancer Center, discusses the potential of antibody-drug conjugates, as a new category of therapy for patients with cancer.

Dr. Lo-Coco on Arsenic Trioxide in Acute Promyelocytic Leukemia

February 12th 2013

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide, in acute promyelocytic leukemia.